SCHEMBL10224252

SCHEMBL10224252

Cc1ccc(S(=O)(=O)N2CCc3nc(C(=O)NO)ccc3C2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 3/20 0.47
▸ HDAC1 Q13547 3/20 0.46
▸ HDAC3 O15379 2/20 0.46
▸ HDAC2 Q92769 2/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC9 Q9UKV0 1/20 0.46
▸ HDAC5 Q9UQL6 1/20 0.46
▸ CD4 P01730 6/20 0.46
▸ F10 P00742 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ BLM P54132 1/20 0.42
▸ PAX8 Q06710 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ OPRM1 P35372 1/20 0.42
▸ OPRD1 P41143 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15048461 0.86 HDAC6 (0.65) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL721799 0.84 TSHR (0.48) HDAC6LMNAMAPTRECQL
SCHEMBL10224213 0.84 DRD2 (0.44) HDAC6F10LMNASMN1; SMN2MAPT
SCHEMBL10207690 0.82 HDAC6 (0.41) HDAC6CD4F10TDP1LMNA
SCHEMBL10224216 0.82 HDAC1 (0.50) HDAC6HDAC1HDAC8LMNAAKR1C3
SCHEMBL13983878 0.79 CD4 (0.51) CD4
SCHEMBL10224240 0.78 HDAC6 (0.53) HDAC6HDAC1HDAC3HDAC2HDAC4
SCHEMBL1264197 0.77 HDAC6 (0.74) HDAC6HDAC1HDAC8OPRM1OPRD1
SCHEMBL720241 0.77 HDAC1 (0.47) HDAC1HDAC8F10MAPT
SCHEMBL4751184 0.77 KDM4E (0.52) CD4LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249142-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-02-02 — — US disclosed
US-20150105418-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2015-04-16 — — US disclosed
US-8952163-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-02-10 — — US disclosed
US-20140142108-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARM INC (US) 2014-05-22 — — US disclosed
US-8471026-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-25 — — US disclosed
US-20120053201-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053201-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 HDAC6 1/4885HDAC1 2/4885HDAC3 5/4885
US-20140142108-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 HDAC6 1/4885HDAC1 2/4885HDAC3 5/4885
US-20150105418-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 HDAC6 1/4885HDAC1 2/4885HDAC3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback